Chimerix Inc
NASDAQ:CMRX
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| US |
|
Chimerix Inc
NASDAQ:CMRX
|
787.5m USD |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
403.9B USD |
Loading...
|
|
| US |
|
Astria Therapeutics Inc
NASDAQ:ATXS
|
326.4B USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
204.6B USD |
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
185.7B USD |
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
122.5B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
82.7B USD |
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
43B EUR |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
70.5B AUD |
Loading...
|
Market Distribution
| Min | -24 813% |
| 30th Percentile | 28.9% |
| Median | 43% |
| 70th Percentile | 60.5% |
| Max | 10 905 714.3% |
Other Profitability Ratios
Chimerix Inc
Glance View
Chimerix, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of pharmaceutical products. The company is headquartered in Durham, North Carolina and currently employs 87 full-time employees. The company went IPO on 2013-04-11. The firm is focused on discovering, developing and commercializing medicines that address unmet medical needs. The firm offers TEMBEXA (brincidofovir) is an antiviral for the treatment of smallpox in all age groups, including infants, and for patients who have difficulty swallowing. The firm's product Imipridones is a cancer therapies, which provides ONC201 for brain and other cancers, ONC206 for central nervous system cancer and ONC212 for pancreatic cancer and leukemia. The Company’s DSTAT is a glycosaminoglycan derivative of heparin, which is a treatment for hematologic malignancies, including newly diagnosed acute myeloid leukemia (AML) in combination with standard chemotherapy.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Chimerix Inc is 100%, which is above its 3-year median of 99.7%.
Over the last 3 years, Chimerix Inc’s Gross Margin has increased from -17.5% to 100%. During this period, it reached a low of -17.5% on Mar 31, 2022 and a high of 100% on Jan 31, 2025.
